Scholarlink

<p>Bilastine is a non-sedating, highly selective H1-antihistamine with proven efficacy and safety in treating allergic rhinoconjunctivitis and urticaria in adults and children. Allergic conjunctivitis, a common ocular condition, negatively impacts quality of life. Topical eye drops are the standard treatment, though ocular bioavailability is often low. Incorporating biopolymers such as hyaluronic acid (HA) into topical formulations enhances adhesive properties, prolongs retention on the ocular surface, and ultimately improves drug bioavailability. This study evaluated the new multidose preservative-free bilastine 0.6% solution with sodium HA against eight commercially available antiallergic eye drops. Using an ex vivo bovine cornea model, bilastine 0.6% demonstrated the highest bioadhesion strength (0.025&#xa0;mJ), indicating superior retention on the ocular surface. It also showed strong protective effects against in vitro dehydration, mainly due to the presence of HA, and did not exhibit cytotoxicity in human primary conjunctival cells. In wound healing assays, preservative-free ketotifen 0.025%, bilastine 0.6%, and azelastine 0.05% promoted corneal wound repair at 72&#xa0;h, outperforming preserved formulations. Overall, preservative-free bilastine 0.6% with HA enhances corneal hydration, retention, and re-epithelialization in vitro, suggesting potential benefits for the management of allergic conjunctivitis and offering promising advancements in treating this widespread condition.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The new bilastine eye drop formulation protects against conjunctival dehydration and promotes corneal wound healing in a comparative in vitro study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月7日

查看全文
  • Eider Arana,
  • Ana Gonzalo,
  • Noelia Andollo,
  • Miguel Pérez-Garrastachu,
  • Francisco Otero-Espinar,
  • Victoria Díaz-Tomé,
  • Felipe Goñi-de-Cerio,
  • Paloma Gómez-Fernández,
  • Gonzalo Hernández,
  • Tatiana Suárez-Cortés

摘要

Bilastine is a non-sedating, highly selective H1-antihistamine with proven efficacy and safety in treating allergic rhinoconjunctivitis and urticaria in adults and children. Allergic conjunctivitis, a common ocular condition, negatively impacts quality of life. Topical eye drops are the standard treatment, though ocular bioavailability is often low. Incorporating biopolymers such as hyaluronic acid (HA) into topical formulations enhances adhesive properties, prolongs retention on the ocular surface, and ultimately improves drug bioavailability. This study evaluated the new multidose preservative-free bilastine 0.6% solution with sodium HA against eight commercially available antiallergic eye drops. Using an ex vivo bovine cornea model, bilastine 0.6% demonstrated the highest bioadhesion strength (0.025 mJ), indicating superior retention on the ocular surface. It also showed strong protective effects against in vitro dehydration, mainly due to the presence of HA, and did not exhibit cytotoxicity in human primary conjunctival cells. In wound healing assays, preservative-free ketotifen 0.025%, bilastine 0.6%, and azelastine 0.05% promoted corneal wound repair at 72 h, outperforming preserved formulations. Overall, preservative-free bilastine 0.6% with HA enhances corneal hydration, retention, and re-epithelialization in vitro, suggesting potential benefits for the management of allergic conjunctivitis and offering promising advancements in treating this widespread condition.